Accelerate drug development           Proteomics technology           

 IBI Research Program: Cancer

Protein quantitative and qualitative modulations are prominent at the onset and clearance of cancer. Entire set of proteins can be up- or down-regulated at various stages of cancer development. Some proteins have also been implicated as biomarkers for cancer diagnosis through the existence of structural variations such as point mutations or posttranslational modifications. Detecting specific changes on the protein level will promote early cancer detection, even before the symptomatic manifestation of the disease.

IBI's cancer program entails the discovery and validation of protein biomarkers for early indication of cancer. Samples such as plasma and urine are obtained through minimally invasive sample collection methods and assayed in a high-throughput mode via the MASSAY™ system and technologies. To date the approach has produced several leads that can be correlated with the early onset, clearance, or treatment of cancer.

Explore this section
Cardiovascular Disease
Neurodegenerative Disorders
Infectious Diseases

Related information
Proteomics technology
Request information

Home | Sitemap | Directions | Literature